Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 5.93 1.02% 0.06
BCRX closed up 1.02 percent on Wednesday, May 23, 2018, on 59 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical BCRX trend table...

Date Alert Name Type % Chg
May 23 180 Bullish Setup Bullish Swing Setup 0.00%
May 23 Overbought Stochastic Strength 0.00%
May 22 Narrow Range Bar Range Contraction 1.02%
May 22 NR7 Range Contraction 1.02%
May 22 NR7-2 Range Contraction 1.02%
May 21 NR7 Range Contraction 2.24%
May 21 Inside Day Range Contraction 2.24%
May 21 Down 3 Days in a Row Weakness 2.24%
May 18 Slingshot Bullish Bullish Swing Setup 0.85%
May 18 Upper Bollinger Band Walk Strength 0.85%

Older signals for BCRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.67
52 Week Low 3.95
Average Volume 745,798
200-Day Moving Average 5.0208
50-Day Moving Average 5.1906
20-Day Moving Average 5.475
10-Day Moving Average 5.799
Average True Range 0.2704
ADX 17.3
+DI 25.13
-DI 16.4
Chandelier Exit (Long, 3 ATRs ) 5.3388
Chandelier Exit (Short, 3 ATRs ) 5.5712
Upper Bollinger Band 6.2562
Lower Bollinger Band 4.6938
Percent B (%b) 0.79
BandWidth 28.536986
MACD Line 0.2379
MACD Signal Line 0.1969
MACD Histogram 0.041
Fundamentals Value
Market Cap 476.94 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -9.56
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.16
Resistance 3 (R3) 6.14 6.05 6.12
Resistance 2 (R2) 6.05 5.99 6.06 6.10
Resistance 1 (R1) 5.99 5.96 6.02 6.01 6.09
Pivot Point 5.90 5.90 5.92 5.91 5.90
Support 1 (S1) 5.84 5.84 5.87 5.86 5.77
Support 2 (S2) 5.75 5.81 5.76 5.76
Support 3 (S3) 5.69 5.75 5.74
Support 4 (S4) 5.71